CoChat

Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial

Open access
Qin, Yu, Zhou, Yong, Chen, Shi-Hui, Zhao, Xiao-Lan, Ran, Li, Zeng, Xiang-Long, Wu, Ying, Chen, Jun-Li, Kang, Chao, Shu, Fu-Rong, Zhang, Qian-Yong, Mi, Man-Tian · 2015 · PLOS ONE
Cited by 101

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

UNLABELLED: Fish oil has been used effectively in the treatment of cardiovascular disease via triglyceride reduction and inflammation modulation. This study aimed to assess the effects of fish oil on patients with nonalcoholic fatty liver disease (NAFLD) associated with hyperlipidemia. Eighty participants with NAFLD associated with hyperlipidemia were randomly assigned to consume fish oil (n=40, 4 g/d) or corn oil capsules (n=40, 4 g/d) for 3 months in a double-blind, randomized clinical trial. Blood levels of lipids, glucose and insulin, liver enzymes, kidney parameters and cytokines at baseline and the end of the study were measured. Seventy people finished the trial. Plasma concentrations of eicosapentaenoic acid and docosahexaenoic acid significantly increased in the fish oil group after intervention. After adjustment for age, gender and BMI, fish oil significantly decreased fasting serum concentrations of total cholesterol, triglyceride, apolipoprotein B and glucose (by (mean±SD) 0.49±0.43 mmol/L, 0.58±0.89 mmol/L, 0.28±0.33 g/L and 0.76±0.56 mmol/L, respectively, P<0.05), as well as alanine aminotransferase and γ-glutamyl transpeptidase levels (by (median (interquartile)) 9.0(0.5, 21.5) and 7.0(2.2, 20.0) IU/L, respectively, P<0.05), significantly increased serum adiponectin levels (by 1.29±0.62 μg/mL, P<0.001), and reduced serum levels of tumor necrosis factor α, leukotrienes B4, fibroblast growth factor 21 (FGF21), cytokeratin 18 fragment M30 and prostaglandin E2 (by 1.70±1.18 pg/mL, 0.59±0.28 ng/mL, 121±31 pg/mL, 83±60 IU/L and 10.9±2.3 pg/mL, respectively, P<0.001). Corn oil had no effect except for increasing serum creatinine concentrations by 7.7±8.9 μmol/L (P=0.008). The effects of fish oil on lipids, glucose and γ-glutamyl transpeptidase were positively correlated with the reductions of serum FGF21 and prostaglandin E2 concentrations after adjustment for age, gender and BMI (r = 0.275 to 0.360 and 0.261 to 0.375, respectively, P<0.05). In conclusion, our findings suggest that fish oil can benefit metabolic abnormalities associated with NAFLD treatment. TRIAL REGISTRATION: ChiCTR-TRC-12002380.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0133496

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 30

  1. Y Yilmaz, 2010, Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease, Eur J Clin Invest, 40, 887, 10.1111/j.1365-2362.2010.02338.x · DOI · Paper page
  2. H Li, 2010, Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride, J Hepatol, 53, 934, 10.1016/j.jhep.2010.05.018 · DOI · Paper page
  3. H Li, 2013, High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China, J Hepatol, 58, 557, 10.1016/j.jhep.2012.10.029 · DOI
  4. C Giannini, 2013, Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage, J Clin Endocrinol Metab, 98, 2993, 10.1210/jc.2013-1250 · DOI · Paper page
  5. AE Feldstein, 2009, Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study, Hepatology, 50, 1072, 10.1002/hep.23050 · DOI · Paper page
  6. A Guleria, 2013, Patients with non-alcoholic fatty liver disease (NAFLD) have an increased risk of atherosclerosis and cardiovascular disease, Trop Gastroenterol, 34, 74, 10.7869/tg.2012.101 · DOI
  7. H Shapiro, 2011, The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease, Clin Nutr, 30, 6, 10.1016/j.clnu.2010.06.001 · DOI
  8. V Nobili, 2013, Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children, Nutr Metab Cardiovasc Dis, 23, 1066, 10.1016/j.numecd.2012.10.010 · DOI
  9. V Nobili, 2011, Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial, Arch Dis Child, 96, 350, 10.1136/adc.2010.192401 · DOI · Paper page
  10. 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 · DOI · Paper page
  11. A Masood, 2005, A simplified and efficient method for the analysis of fatty acid methyl esters suitable for large clinical studies, J Lipid Res, 46, 2299, 10.1194/jlr.D500022-JLR200 · DOI · Paper page
  12. Y Qin, 2014, Daidzein supplementation decreases serum triglyceride and uric acid concentrations in hypercholesterolemic adults with the effect on triglycerides being greater in those with the GA compared with the GG genotype of ESR-beta RsaI, J Nutr, 144, 49, 10.3945/jn.113.182725 · DOI
  13. J Liu, 2015, The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy, Metabolism, 64, 380, 10.1016/j.metabol.2014.11.009 · DOI
  14. M Yang, 2011, Effects of short-term continuous subcutaneous insulin infusion on fasting plasma fibroblast growth factor-21 levels in patients with newly diagnosed type 2 diabetes mellitus, PLoS One, 6, e26359, 10.1371/journal.pone.0026359 · DOI
  15. K Li, 2009, Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus, Eur J Endocrinol, 161, 391, 10.1530/EJE-09-0335 · DOI · Paper page
  16. A Kharitonenkov, 2007, The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21, Endocrinology, 148, 774, 10.1210/en.2006-1168 · DOI · Paper page
  17. J Villarroya, 2014, Fibroblast growth factor-21 and the beneficial effects of long-chain n-3 polyunsaturated fatty acids, Lipids, 49, 1081, 10.1007/s11745-014-3948-x · DOI
  18. N Siriwardhana, 2012, Health benefits of n-3 polyunsaturated fatty acids: eicosapentaenoic acid and docosahexaenoic acid, Adv Food Nutr Res, 65, 211, 10.1016/B978-0-12-416003-3.00013-5 · DOI · Paper page
  19. AD von Frankenberg, 2014, Effect of dietary lipids on circulating adiponectin: a systematic review with meta-analysis of randomised controlled trials, Br J Nutr, 112, 1235, 10.1017/S0007114514002013 · DOI · Paper page
  20. B Gray, 2013, Omega-3 fatty acids: a review of the effects on adiponectin and leptin and potential implications for obesity management, Eur J Clin Nutr, 67, 1234, 10.1038/ejcn.2013.197 · DOI
  21. F Guebre-Egziabher, 2013, Differential dose effect of fish oil on inflammation and adipose tissue gene expression in chronic kidney disease patients, Nutrition, 29, 730, 10.1016/j.nut.2012.10.011 · DOI
  22. A De Rosa, 2013, Adiponectin oligomers as potential indicators of adipose tissue improvement in obese subjects, Eur J Endocrinol, 169, 37, 10.1530/EJE-12-1039 · DOI
  23. J Salas-Salvado, 2006, Subcutaneous adipose tissue cytokine production is not responsible for the restoration of systemic inflammation markers during weight loss, Int J Obes (Lond), 30, 1714, 10.1038/sj.ijo.0803348 · DOI
  24. A Gammelmark, 2012, Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects, Nutr Res, 32, 15, 10.1016/j.nutres.2011.12.007 · DOI
  25. N Bender, 2014, Fish or n3-PUFA intake and body composition: a systematic review and meta-analysis, Obes Rev, 15, 657, 10.1111/obr.12189 · DOI · Paper page
  26. WL Holland, 2013, An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice, Cell Metab, 17, 790, 10.1016/j.cmet.2013.03.019 · DOI · Paper page
  27. Z Lin, 2015, Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice, Circulation, 131, 1861, 10.1161/CIRCULATIONAHA.115.015308 · DOI · Paper page
  28. K Eto, 2010, Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes, Diabetes Res Clin Pract, 89, 52, 10.1016/j.diabres.2010.03.019 · DOI
  29. A Bisgaard, 2014, Significant gender difference in serum levels of fibroblast growth factor 21 in Danish children and adolescents, Int J Pediatr Endocrinol, 2014, 7, 10.1186/1687-9856-2014-7 · DOI
  30. CY Wong, 2010, Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus, Diabet Med, 27, 54, 10.1111/j.1464-5491.2009.02869.x · DOI · Paper page

Cited by

See all 101

Metadata

Authors
Qin, Y., Zhou, Y., Chen, S.-H., Zhao, X.-L., Ran, L., Zeng, X.-L., Wu, Y., Chen, J.-L., Kang, C., Shu, F.-R., Zhang, Q.-Y., & Mi, M.-T.
Venue
PLOS ONE
Published
2015-07-30
Volume
10
Issue
7
Pages
e0133496
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1929380714
Cited by
101
References
12
FWCI
8.67
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1371/journal.pone.0133496
The paper
Qin, Y., Zhou, Y., Chen, S.-H., Zhao, X.-L., Ran, L., Zeng, X.-L., Wu, Y., Chen, J.-L., Kang, C., Shu, F.-R., Zhang, Q.-Y., & Mi, M.-T. (2015). Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial. PLOS ONE. https://doi.org/10.1371/journal.pone.0133496

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.